Drugs / EBP921
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01316185 | Jan 2011 → Apr 2013 | hepatitis D virus infection | Eiger BioPharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBP921 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01316185 ↗ |
| Action | Inhibit | “a prenylation inhibitor” NCT01316185 ↗ |